江苏浩欧博生物医药股份有限公司

Group 1: Company Guarantees - The company provides guarantees for its wholly-owned subsidiaries to enhance overall financing efficiency, aligning with operational needs [1][2] - The total amount of guarantees provided to subsidiaries is RMB 200 million, accounting for 24.63% of the latest audited net assets and 19.36% of total assets [2] Group 2: Fundraising and Usage - The company raised a total of RMB 555.86 million through its initial public offering, with a net amount of RMB 496.47 million after deducting related expenses [5][6] - As of December 31, 2024, the company has strictly adhered to its fundraising management policies, ensuring funds are stored in dedicated accounts and used appropriately [7][8] Group 3: Fund Management and Investment - The company has not used idle fundraising for temporary working capital or to repay bank loans as of December 31, 2024 [9][11] - The company has approved the use of up to RMB 200 million of temporarily idle funds for cash management, ensuring safety and liquidity [9][10] Group 4: Project Updates - The company has decided to conclude certain fundraising projects and extend the timeline for others, specifically the "New In Vitro Diagnostic Reagent R&D Center Project" to September 2025 [12][13] - There are no changes in the use of funds for fundraising projects as of December 31, 2024 [14] Group 5: Compliance and Verification - The company has received positive verification from its accounting firm regarding the management and usage of fundraising, confirming compliance with relevant regulations [16][17]